University of Ioannina   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Ioannina Greece (1964)

Organization Overview

First Clinical Trial
1999
NCT00005053
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Assistant Professor of Oncology, Medical School, University of Ioannina | Department of Medical Oncology, Medical School, University of Ioannina | Department of Neurology, University of Ioannina | Laboratory of Biotechnology, Department of Biological Applications & Technology, University of Ioannina | University of Ioannina | University of Ioannina Department of Medicine | University of Ioannina Hospital, Medical School | University of Ioannina Medical School | University of Ioannina, School of Health Sciences, Department of Medicine, Laboratory of Physiology | University of Ioannina School of Medicine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Blister (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Dyskinesias (Phase 2)

Dyslipidemias (Phase 4)

Gait Disorders, Neurologic (Phase 1)

Glioblastoma (Phase 2)

Hemiplegia (Phase 1)

Hypercholesterolemia (Phase 4)

Hyperlipidemia, Familial Combined (Phase 4)

Hyperlipidemias (Phase 4)

Hyperlipoproteinemias (Phase 4)

Ischemia (Phase 4)

Lung Neoplasms (Phase 2)

Metabolic Syndrome (Phase 4)

Neoplasm Metastasis (Phase 4)

Pancreatic Neoplasms (Phase 2)

Parkinson Disease (Phase 2)

Peripheral Arterial Disease (Phase 4)

Prostatic Neoplasms (Phase 2)

Respiratory Aspiration (Phase 3)

Scoliosis (Phase 2)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial APIs: 37